Xencor, Inc.
Clinical trials sponsored by Xencor, Inc., explained in plain language.
Biotech engineering antibody therapeutics for cancer and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kidney cancer: experimental drug XmAb819 enters human trials Results expected Feb 2027 (estimated)
- First human trial of a new antibody drug begins Results expected May 2027 (estimated)
-
Experimental lung cancer drug trial halted early
Disease control Stopped earlyThis early-stage trial tested a new immunotherapy drug called vudalimab combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It compared this combination to the standard treatment of pembrolizumab plus chemotherapy. The study was terminated ear…
Phase 1/2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental drug XmAb27564 tested for skin conditions – trial halted early
Disease control Stopped earlyThis early-stage trial tested an experimental drug called XmAb27564 in 23 people with mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis. Participants received four doses of the drug or a placebo every two weeks. The main goal was to check safety and tolerabi…
Phase 1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC